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Long-term drug survival and predictor analysis of the whole psoriatic patient population on 
biological therapy in Hungary 
 
 
Abstract  
 
Persistence is an important component of therapeutic success, which depends on a variety of 
factors. Persistence measured under optimal conditions during clinical trials does not necessarily 
coincide with persistence observed in the real-world settings.   
The aim of the present study was to compare persistence rate of TNF-alpha inhibitors and 
interleukin 12/23 inhibitor in all psoriasis patients in Hungary, as well as to analyze the predictors 
of persistence. Data collected from 1263 patients over a period of 46 months were subjected to a 
retrospective analysis. Drug survival rate has been calculated according to Kaplan-Meier analysis 
and Cox regression was used to study the predictors.  
The overall persistence rate for the 4 biologicals exceeded 60% after 3 years. The persistence rate 
of ustekinumab at 3 years was 67.83%, which was superior compared to that of the TNF-alpha 
inhibitors, where the mean persistence rate was shown to be 50.76% (p<0.05). Male patients 
showed significantly higher persistence than females (HR = 0.76, p<0.05 CI: 0.63, 0.92). Age, 
therapy naïve status and use of concomitant MTX did not have significant effect on drug 
survival. Persistence rate of ustekinumab was significantly higher than that of TNF-alpha 
inhibitors, and among predictors, only male gender influenced persistence significantly. 
 
Key words: biological therapy, comparison, hazard ratios, persistence, predictors, psoriasis 
 
 
 
 
 
 
 
 
 
 
Page 3 of 44
http://mc.manuscriptcentral.com/jdt
Journal of Dermatological Treatment  www.informaworld.com/jdt
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
3 
 
Introduction  
 
Psoriasis is a common, chronic, immune-mediated skin disease. The disease and the 
comorbidities that frequently develop during its course not only impact the quality of life 
negatively, but also worsen life expectancy [1,2]. Epidemiological studies have shown that 
psoriasis patients have shorter life expectancy, particularly those who develop cardiovascular 
comorbidities [1]. Even though the disease is currently not curable, there are a number of 
therapeutic options which ensure a symptom-free status, although requires a long-term, often life-
long treatment [3,4]. Optimal drug survival is fundamental in the management of psoriasis and 
comorbidities [5]. 
Drug survival, i.e. persistence, is a comprehensive measure of therapeutic success, which depends 
on a variety of factors, including efficacy, safety, tolerability and patient satisfaction [5].   
Suboptimal persistence is a common and complex problem among patients with chronic diseases, 
including psoriasis [6, 7, 8]. Frequent switches between therapies and clinical research aiming to 
develop new therapeutic options to address persistence issues both confirm this [6]. An important 
breakthrough was the development of biological therapies, which became available for the 
treatment of moderate to severe psoriasis.  Biological therapies that are now widely available for 
psoriasis patients and include the TNF-α inhibitor adalimumab, infliximab, etanercept, the IL-
12/23 inhibitor ustekinumab, as well as the IL-17 inhibitor secukinumab and ixekizumab.   
 
Drug survival rate of biologicals seems to be better compared to local and conventional systemic 
therapies [9]. Persistence measured under optimal (standardized) conditions in prescreened, 
highly motivated patient populations, using tight protocols and independent investigators during 
clinical trials does not necessarily coincide with the drug survival of therapies prescribed in the 
real-world settings [10,11]. There are studies on the short-term persistence of biological therapies 
used in psoriasis, however, very limited comparative evidence is available on the long-term 
persistence of biological therapies used in the real-world settings [12]. The objectives of this 
study were to analyze the characteristics of all psoriasis patients treated with any of the biological 
therapies currently marketed in Hungary (adalimumab, etanercept, infliximab, ustekinumab), to 
compare long-term drug survival of such therapies in the real-world settings, and also to assess 
the impact of additional factors, like patient age, gender, biological therapy naïve status or the use 
of methotrexate (MTX) on drug survival.   
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Methods  
 
Patient enrollment  
The data source for this retrospective analysis was the database of the Hungarian National Health 
Insurance Fund (NHIF), which ensured the comparative analysis of all relevant data collected in 
the real-world settings. NHIF’s database covers healthcare data of the entire Hungarian 
population (nearly 10 million people) and allows identifying all patients in Hungary with a record 
of any reimbursed drug prescription and provides non-identified patient data on healthcare 
services and medical outcomes. Based on the available data provided by NHIF, it was possible to 
analyze patients’ age and gend r, onset of disease, the collected data of in- and outpatient care 
and previous therapies. As the NHIF database includes PASI and DLQI scores of psoriasis 
patients only since February 2012, PASI and DLQI scores were obtained from the registries of 
participating university centers instead of the NHIF database.  In Hungary patients suffering from 
psoriasis are eligible for biologic treatment in case of severe disease (PASI ≥ 15 or BSA ≥ 10 or 
DLQI ≥ 10) and documented intolerance or contraindication of standard systemic treatments. 
Hungarian Guideline on Psoriasis Therapies is based on and synchronized with the European S3 
Psoriasis Guideline in accordance with the financing protocol of the NHIF [13].  
All psoriasis patients, who started at least one biological therapy in Hungary, within the 46-
months study period from 1 June, 2010 to 1 April, 2014, were enrolled in this study.  Data of 
1574 treatment episodes of 1263 patients were analyzed (since some patients received more than 
one biological therapy over the study period, the number of treatment episodes exceeded the 
number of patients).  
Treatment discontinuation was defined by the occurrence of any of the following events: 
termination (no more prescription) or reinduction of the biological therapy (at least 180 days 
pause of biological therapy until the next prescription1), or switching to a different biological 
                                   
1
 Sensitivity analysis was carried out in order to identify the most appropriate gap length for treatment 
discontinuation. After a 180 day gap in the biological treatment there were only very limited number of patients 
who continued on the same treatment with no other biological treatment in between. These cases were 
considered as reinduction of biological therapy. 
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therapy. There were several reasons of treatment discontinuation however this kind of data were 
not captured in the NHIF registry. Since the authors have used the database of the NHIF no 
information was available on the reason of therapy discontinuation. Data were censored for 
patients where death of any cause occurred over the study period.  
 
 
Statistical methods applied  
 
Kaplan-Meier survival curve was used for the comparative analysis of drug survival. Cox 
proportional hazard model was applied to analyze the impact of patient age, gender, biological 
therapy naïve status and additional MTX therapy on drug survival. In order to compare patients’ 
baseline characteristics, conservative WALD test was used. ANOVA test, i.e. two-factor variance 
analysis was used to compare PASI and DLQI scores of treated patients as these are continuous 
variables. Mean PASI and DLQI scores were calculated using data collected from 641 patients 
treated by the 4 university centers.  
 
 
 
Results  
 
Patients’ baseline characteristics 
 
Data collected from a total number of 1263 patients were analyzed. Demographic data of patients 
are shown in Table 1.  
Although the vast majority of the enrolled patients, (n=972, 76.96%) received only one biological 
therapy over the study period, 18.69% (n=236) and 4.35% (n=55) of the patients were 
administered 2 and 3 or more biological therapies, respectively.  Since certain patients could have 
received several biological therapies due to the therapeutic switches, the number of treatment 
episodes (1574) exceeded the total patient number. All further data will refer to treatment 
episodes. 
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Patients’ characteristics were also analyzed and compared between subgroups receiving different 
biological therapies (Table 2).  The most frequently administered therapies were adalimumab and 
ustekinumab (n=491 and n=487, respectively), followed by etanercept (n=330), and infliximab 
(n=266) The analysis of each therapeutic groups showed that the distribution by gender, age and 
additional MTX usage was comparable among the different therapeutic groups, however, the 
ratio of biological therapy naïve patients was significantly different between the infliximab and 
adalimumab groups as well as between the ustekinumab and TNF-alpha inhibitors groups 
(p<0.05). Table 2 shows side-by-side comparison of data of various treatment groups comparing 
patient age, gender, additional MTX therapy, and biological therapy naïve status. Possible 
inhomogeneities in different treatment groups were handled by using all of these 4 grouping 
variables as covariates in the fitted Cox models, hence the findings on drug survival analysis 
were not impacted by them. The comparison of PASI (p=0.18) and DLQI (p=0.50) scores 
showed no significant differences among the 4 subgroups using different biological therapies.  
 
 
 
 
Drug survival of biological therapies  
 
 
The persistence was calculated by using the Kaplan-Meier method, and illustrated as a survival 
curve (Figure 1). The results of the database analysis showed that the drug survival rate of 
biological therapies in psoriasis patients is high as a whole, since the overall survival rates are 
79.70%, 68.52%, and 60.75% in the first, second, and third year of therapy, respectively. 
The cumulative data of the 3 TNF-alpha inhibitors showed that drug survival probability was 
73.28% in the first year, which dropped to 60.22% in the second year to decrease as low as 
50.76% in the third year.  
Kaplan-Meier survival analysis of the individual TNF-alpha inhibitors showed that drug survival 
of etanercept was 71.96% in the first year, which dropped to 60.03% one year later to reach 
49.49% after the third year. Drug survival of adalimumab and infliximab was 68.98% and 
70.92% in the first year, which dropped to 58.13% and 49.79% one year later to reach 51.95% 
and 36.26% after the third year respectively. The comparison of the drug survival rates of the 3 
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TNF-alpha inhibitors showed that adalimumab had the highest probability of patients staying on 
the therapy for three consecutive years, although based on Cox model results no significant 
difference among the 3 therapies could be detected. 
Drug survival rate of ustekinumab was 86.50% in the first year, 74.17% in the second year, and 
67.83% after the third year. The comparison of drug survival rates of ustekinumab and TNF-
alpha inhibitors showed that the persistence of ustekinumab was significantly higher if 
persistence was compared head-to-head with the TNF-alpha inhibitors (p<0.05), and this 
difference also persisted if ustekinumab was compared to the cumulative data of the 3 TNF-alpha 
inhibitors (p<0.05).  
 
Predictors of biological survival  
 
 
The Cox regression analysis of the impact of predictors such as patient age, gender, biological 
therapy naïve status and additional MTX use on persistence is shown in Figure 2. The analysis of 
all biological therapies together revealed that the probability of staying on the therapy was 
significantly higher in male patients than in female patients (p < 0.05, CI: 0.63, 0.92). Therapy 
naïve status, older age and the use of MTX all decreased the risk of dropping out of therapy, 
although the impact was not significant (Figure 2).  
The analysis of the cumulative data of all TNF-alpha inhibitor therapies revealed that the impact 
of patient gender was significant on drug survival: the risk of discontinuing the therapy was 0.71 
times lower for male patients compared with female patients. (HR=0.71, p<0.05, CI: 0.58, 0.87).  
The analysis of the individual therapy groups revealed the following: male gender had a 
favorable impact on the persistence of adalimumab (HR=0.73, p<0.05 CI: 0.54, 0.99) and 
infliximab (HR=0.71, p<0.05, CI: 0.49, 1) but did not influence the persistence of etanercept. 
Patients over 40 years on etanercept showed a significantly better persistence on the drug than 
patients younger than 40 years of age (HR=0.57, p<0.05, CI: 0.4, 0.81). None of the investigated 
predictors had a significant impact on drug survival of ustekinumab.   
 
Discussion 
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Suboptimal persistence was identified as a significant drawback in the management of psoriatic 
patients, which considerably hinders successful therapy, and can result in therapy discontinuation 
and increased treatment costs [6,7]. No conclusive findings have been reached so far regarding 
the long-term drug survival rates of biological therapies in psoriasis and predictors of their 
persistence. This study is the first long-term study performed in Hungary on the whole psoriatic 
patient population treated with biologicals, to analyze the drug survival of all available biological 
therapies and to investigate predictors of persistence in the real-life settings.  A further advantage 
of this study is that this is the first comprehensive analysis on this topic in the literature using the 
database of the NHIF of a given country.  
The analysis of the present study population showed that adalimumab and ustekinumab were 
administered to almost equal numbers of patients, while infliximab and etanercept were also used 
in identical proportions, although less commonly than the first two agents. Since all four 
biological therapies can be used under the same circumstances in Hungary, the choice of drug 
depended mostly on dermatologists’ preferences. The comparison of the subgroups receiving 
different biological therapies revealed that although there were certain differences among the 4 
therapy groups in terms of patients’ biological therapy naïve status, ultimately this factor didn’t 
prove to have statistically meaningful effect on drug persistence rate or on predictor analysis, 
since the statistical methods have addressed this issue. At the same time, no significant 
differences were found in terms of PASI and DLQI scores across the subgroups of patients on 
different biologicals. 
The available literature has already shown, that biological therapies used in psoriasis have 
superior drug survival rates compared to the rates seen with conventional systemic therapies [9].  
Nevertheless, until recently there was only a lack of data obtained on large patient population 
treated for long time with TNF-alpha inhibitors and IL-12/23 inhibitor in the real-life settings [11, 
14]. Table 3 summarizes all the studies published so far, where data were collected from large 
patient population of 2 or more centers, the follow-up period was at least one year, and the 
authors compared at least 3 or more biological therapies. The list includes 5 prospective registry-
based studies and 3 retrospective studies [5,11,15,16,17,18,19]. Table 3 shows, that those studies 
which included ustekinumab have found drug survival of ustekinumab superior to the drug 
survival of TNF-alpha inhibitors.  The largest study was published by Menter et al. analyzing 
data of 4000 patients taken from the PSOLAR registry, and their results indicated that drug 
Page 9 of 44
http://mc.manuscriptcentral.com/jdt
Journal of Dermatological Treatment  www.informaworld.com/jdt
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
9 
 
survival of ustekinumab was better than that of TNF-inhibitors for both biological-naïve and 
biological-experienced patients with psoriasis [19].  This concurs with the results from the British 
register (BADBIR) of 3523 bionaïve patients, where the drug survival rate of ustekinumab has 
been found nearly 80% at 3 years, which is significantly higher than that seen with TNF-
inhibitors [16]. Gniadecki et al. has also performed an updated study involving 1277 psoriasis 
patients treated with biological therapy and found that ustekinumab had the highest survival rate 
(81.9%) at 4 years, followed by adalimumab and infliximab. Between the TNF-inhibitors no 
significant differences were detected [11]. Our results are comparable to the above investigations, 
and showed that drug survival rates of biologic therapies were excellent compared to other 
therapies, even if they diminished over time: 79.70% after the first year, 68.52% after the second 
year and 60% after the third year. At 3 years, drug survival rates were 67.83% of ustekinumab, 
51.95% of adalimumab, 49.49% of etanercept, and 36.26% of infliximab. Our findings also 
showed that drug survival of ustekinumab was superior to TNF-alpha inhibitors, and the 
significant difference persisted over the 3-year study period. Adalimumab was shown to have the 
highest drug survival rate of all TNF- inhibitors studied, however, no significant difference was 
found among these drugs over the 46 months of the study period.  
In addition to the analysis of persistence rates, it is also very important to explore predictors of 
drug survival. No conclusive evidence has yet been provided on the predictors of biological drug 
survival in psoriasis. Studies done so far discussed the role of several factors such as PASI, 
DLQI, comorbidities, age, gender, weight, disease onset,  duration of psoriasis, presence of 
psoriatic arthritis, concomitant MTX or biological therapy naïve status and smoking. In Table 4 
we summarized results of long-term survival analyses performed on large psoriasis patient 
populations, investigating predictors of biological therapies only [11,15,17,19,20]. Three studies 
have shown that female gender is a predictor of discontinuation of biological therapies, 
[11,17,19] however Menter’s data are not directly comparable with the aforementioned studies 
since these authors analyzed biological naïve and experienced patients’ predictors separately. On 
the other hand other predictors of discontinuation like previous treatment with biologics, smoking 
status, higher DLQI, strict adherence to approved dose, presence of comorbidities, were detected 
only in one of the aforementioned investigations [11,15,17,19,20].  
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In the present study factors which could be extracted from the database of the NFIH were 
investigated. In accordance with the aforementioned authors, we could demonstrate the positive 
impact of male gender on the persistence of infliximab and adalimumab, while it had no effect on 
the persistence of ustekinumab and etanercept. It is not yet clear how gender impacts the 
persistence of biological therapy in psoriasis, but remarkably, female rheumatoid arthritis patients 
are also more likely to discontinue therapy than males [21]. Possible hypothetical explanations 
could be that female patients may develop anti-drug antibodies more frequently resulting in 
decreased therapeutic efficacy, or alternatively, psychological factors, such as dissatisfaction with 
treatment, may play more important role in females, but until now comparative studies were not 
performed.  
In our study in the etanercept group, patients over 40 years were more likely to stay on the 
therapy than their younger peers. To our knowledge, no other previous investigations showed 
similar effect of age on the persistence of biological therapies.  
In our study biological naive status and the use of MTX all decreased the risk of dropping out of 
therapy, although the impact was not significant. Biological therapy naïve status was shown to be 
a positive predictor for persistence in psoriasis by Gniadecki et al., and, similarly, Lopez-Ferrer 
could also demonstrate reduction of adalimumab drug survival in patients with prior exposure to 
another TNF-alpha inhibitor. On the other hand, there are studies which, similar to the current 
study did not find previous biological therapy usage as a negative predictor of persistence 
[11,15,19,20,23]. Although concomitant MTX usage has been shown to be associated with a 
better persistence of biologicals in rheumatological settings, there is no conclusive evidence in 
psoriasis about additional MTX as a positive predictor [24,25]. In a systematic review Bezooijen 
et al. selected eight studies, which generally showed that combination therapy of biologicals and 
MTX had higher efficacy than biological monotherapy, which could also indicate a positive 
effect of MTX on the drug survival, however, persistence was not investigated in this study [26]. 
On the other hand, Menter and colleagues unexpectedly reported that patients receiving MTX 
were significantly more likely to discontinue biological treatment compared with those without 
concomitant MTX in bionaïve  group, but not in biologic experienced patients [19]. Our present 
study did not show any significant impact of the addition of MTX to the biological therapy on 
drug survival rates of any of the biological drugs studied.  
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Based on the findings of this study drug survival rates of biologic therapies can be 
regarded as excellent as the vast majority of the patients (nearly 80%) received only one 
biological over the 3 years’ study period, and the mean survival rate did not diminish below 60% 
even after 3 years.  The IL-12/23 inhibitor ustekinumab was shown to have significantly better 
drug survival rate than the TNF-alpha inhibitors, and when analyzing consolidated data of all 
assessed biologic therapies, male patients had better persistence than female patients.  One of the 
advantages of the present study is that it is based on real-life data from the NHIF database, which 
allowed to analyze the whole psoriatic patient population treated with biological therapy in 
Hungary over a long period of time. 
 
 
Limitations of the study 
 
This is a retrospective analysis. Since the authors have used the database of the NHIF no 
information is available on the reason of therapy discontinuation. It is also worthwhile 
mentioning that while there is a patient support program for ustekinumab with potential impact 
on drug survival rates, there is no information available as to the existence of similar programs 
for the TNF-inhibitors.   An additional limitation of the study is that the NHIF database did not 
include the PASI and DLQI scores of patients on biological therapies, and, therefore, such data 
were taken from the databases of the participant university centers, and, as such, the data do not 
cover the full patient population.   
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Tables and figures 
 
 
 
 
       Table 1 Characteristics of the study population 
 
Number of patients 1263 
Mean age in years (SD) 49.3 (14.3) 
Male / female (%) 61.3 / 38.7 
Patients under 40 years / 40 years or above 
(%) 
29.3 / 70.7 
Biological therapy naïve / previously treated 
(%) 
81.3 / 18.7 
Number of patients receiving MTX in addition 
to the biological therapy  
97  
Mean PASI (SD) 20.5  (6.4) 
Mean DLQI (SD) 20.0  (5.8) 
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Table 2 Baseline characteristics of patients receiving different biological therapies and pairwise 
comparison of the 4 groups regarding gender, age, ratio of biological naïve patients and MTX 
usage 
 
 Therapy Adalimumab Etanercept Infliximab Ustekinumab 
Treatment episodes (1574) 491 (31.2%) 330 (21.0%) 266 (16.8%) 487 (31.0%) 
Mean age (SD) 47.24  (13.77) 47.55  (15.39) 49.92  (13.63) 47.71  (13.31) 
Male / Female % 59.1% / 40.9 56.4% / 43.6  64.3% / 35.7 61.4% / 38.6 
Patients under 40 years / 40 
years or above (%) 
33.0 / 67.0  31.5 / 68.5 22.9 / 77.1 31.2 / 68.8 
Biological therapy naïve / 
previously treated (%) 
64.4 / 35.6 73.2 / 26.8 77.8 / 22.2 50.1 / 49.9 
Patients receiving methotrexate 
in addition to the biological 
therapy (treatment episode) 
40 16 26 32 
P values of the conservative Wald tests, adjusted  
for the pairwise comparison of the proportion of  
 
gender  
Adalimumab - 1 1 1 
Etanercept 1 - 0.972 1 
Infliximab 1 0.972 - 1 
Ustekinumab 1 1 1 - 
 
age groups 
Adalimumab - 1 0.192 1 
Etanercept 1 - 0.385 1 
Infliximab 0.192 0.385 - 0.385 
Ustekinumab 1 1 0.385 - 
biological naïve patients  
Adalimumab - 0.106 0.012* 0.004* 
Etanercept 0.106 - 0.356 <0.001* 
Infliximab 0.012* 0.356 - <0.001* 
Ustekinumab 0.004* <0.001* <0.001* - 
patients receiving MTX in addition to the biological therapy  
Adalimumab - 0.85 1 1 
Etanercept 0.85 - 0.6 1 
Infliximab 1 0.6 - 1 
Ustekinumab 1 1 1 - 
Data are reported for treatment episodes   
*significant differences 
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Table 3 Studies on long term drug survival of biological therapies in psoriasis  
 
Data of those studies are summarized, which investigated persistence of at least 3 biologicals and 
were collected on large psoriasis patient population of 2 or more centers and over long follow up 
period (least one year). IFN: infliximab, ADA: adalimumab, ETN: etanercept, UST: ustekinumab 
 
 
 
 
 
 
Study Biologics 
Patients/Treatme
nt periods 
Follow-up 
time 
(months) 
Best survival 
Source/ 
regimen 
R. Gniadecki et 
al. (2011) 
ADA, ETN, 
INF 
 
747 patients/882 
treatment episodes 
 
48 INF (70%) 
DERMBIO; Danish 
prospective registry 
M. Esposito et 
al. (2013) 
ADA, ETN, 
INF 
650 patients 28.9 ± 15.4 ETN (72.6%)  
Retrospective analysis 
from three Italian 
referral centers 
van der Reek et 
al. (2014) 
ADA, ETN, 
UST 
249 treatment 
episodes 
12 UST (85%) 
Bio-CAPTURE Dutch   
prospective registry  
R.B. Warren et 
al. (2015) 
ADA, ETN,  
INF, UST 
3523 patients 36 UST 
BADBIR registry; 
Prospective British 
cohort study 
R. Gniadecki et 
al. (2015) 
ADA, ETN, 
INF, UST 
1277 patients/1867 
treatment episodes 
followed for 
up to 10 
years 
UST (81.9% 
after 5 years) 
DERMBIO Danish 
prospective registry 
E. Vilarrasa et 
al. (2016) 
ADA, ETN, 
INF, UST 
427 patients/703 
treatment episodes 
48  UST  
retrospective study, 
from 2 Spanish center 
A. Menter et al 
(2016) 
ADA, ETN, 
INF, UST 
4000 patients 74  UST 
PSOLAR; prospective 
registry from USA and 
European countries 
L. Pogácsás et 
al. (2016) 
ADA, ETN, 
INF, UST 
1263 patients/1574 
treatment episodes 
46 UST 67.83% 
retrospective study, 
database of NHIF, 
Hungary 
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Table 4 Studies on the predictors of biological therapies in psoriasis 
 
 
Study Biologics 
Examined 
predictors/covariates 
Significant covariates 
R. Gniadecki et al. (2015) 
INF, ADA, ETN, UST 
1277 patients/1867 treatment 
episodes 
age, sex, previous biologic 
treatment, weight, duration 
of psoriasis, presence of 
PsA, baseline PASI and 
DLQI, concomitant MTX, 
number of co-morbidities 
predictors of 
discontinuation: female 
gender; previous biologic 
treatment  
R.B. Warren et al. (2015) 
INF, ADA,  ETN, UST 
3523 patients 
age, sex, BMI, smoking 
status, presence of PsA, 
number of co-morbidities, 
disease duration, disease 
onset, PASI, DLQI, 
unstable psoriasis, 
concomitant MTX, 
concomitant cyclosporine 
predictors of 
discontinuation: female 
gender, being current 
smoker, higher DLQI 
predictors of drug 
survival: presence of PsA 
A. Menter et al. (2016) 
INF, ADA, ETN, UST 
4000 patients 
age, gender, ethnicity, 
BMI, familial psoriasis 
history, smoking status, 
alcohol use status, duration 
of psoriasis, age at the 
diagnosis of psoriasis, 
presence of PsA, study 
site/geographic region, 
history of 
immunmodulator use, 
types of insurance, 
previous biologic 
treatment, reasons for 
discontinuation of prior 
biologics, PSA, 
concomitant MTX use 
predictors of 
discontinuation: in bio 
naïve patients: 
concomitant MTX, female 
gender and geographic 
region (North America vs. 
Latin America) 
E. Vilarrasa et al. (2016) 
INF, ADA,  ETN, UST 
427 patients 
sex, presence of PsA, 
biologic naïve status, use 
of combination treatment, 
weight, strict adherence to 
approved doses, PASI75 
and PASI 90 response 
predictors of 
discontinuation obesity,  
strict adherence to 
approved doses;  
predictors of drug 
survival: PASI75 and 
PASI90 response at week 
16  
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A. Jacobi et al. (2016) 
INF, ADA, ETN, UST, 
Efalizumab 
125 treatment episodes 
biologic naïve status, 
presence of PsA, and 
comorbidity with the 
presence of metabolic 
syndrome 
 
predictors of 
discontinuation: 
comorbidities  
 
predictors of drug 
survival: presence of PsA 
L. Pogácsás et al. (2016) 
INF, ADA, ETN, UST 
1263 patients/1574 treatment 
episodes 
gender, age, additional 
MTX therapy, biologic 
naïve status 
predictors of 
discontinuation: female 
gender 
Data of those studies are summarized, which investigated predictors of at least 3 biologicals and 
were collected on large psoriasis patient population and over long follow up period (least one 
year).  
IFN: infliximab, ADA: adalimumab, ETN: etanercept, UST: ustekinumab MTX: methotrexate 
PASI: psoriasis area severity index, DLQI: Dermatology Life Quality Index 
PSA: Physician’s Global Assessment  
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Fig. 1. Kaplan-Meier survival curve of the 4 biologicals individually and in summary (all 
biological therapies). Data include 1574 treatment episodes. 491 adalimumab treatment series, 
330 etanercept series, 266 infliximab series, and 487 ustekinumab series.  
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Predictors of biological survival  
 
 
 
Fig. 2. Multivariate analysis of predictors on biological therapies’ persistence rate (Cox 
proportional hazard and regression model). The figure shows the risk of drop out of therapy by 
predictors such as patient age, gender, biological therapy naïve status and additional MTX usage. 
1Reference category: Age<=40 
2Reference category: female gender 
3Reference category: biological-experienced patients 
4Reference category: patients who do not receive MTX 
Outcome Variables and Covariates
Adalimumab therapy switch
Age
1
: Age>=40
Gender
2
: Male
Naivity
3
: Naiv
Methotrexate
4
: Received
Etanercept therapy switch
Age
1
: Age>=40
Gender
2
: Male
Naivity
3
: Naiv
Methotrexate
4
: Received
Infliximab therapy switch
Age
1
: Age>=40
Gender
2
: Male
Naivity
3
: Naiv
Methotrexate
4
: Received
TNF-α therapies switch
Age
1
: Age>=40
Gender
2
: Male
Naivity
3
: Naiv
Methotrexate
4
: Received
Ustekinumab therapy switch
Age
1
: Age>=40
Gender
2
: Male
Naivity
3
: Naiv
Methotrexate
4
: Received
All therapies switch
Age
1
: Age>=40
Gender
2
: Male
Naivity
3
: Naiv
Methotrexate
4
: Received
HR & p value 
1.11 (0.55) 
0.73 (0.026)* 
0.9 (0.481) 
0.71 (0.244) 
0.57 (0.002)* 
0.85 (0.329) 
1.29 (0.195) 
0.79 (0.686) 
0.73 (0.107) 
0.71 (0.044)* 
0.72 (0.109) 
1.02 (0.925) 
0.83 (0.087) 
0.71 (0.001)* 
0.9 (0.315) 
0.66 (0.081) 
0.76 (0.215) 
1.03 (0.568) 
0.72 (0.09) 
0.72 (0.501) 
0.81 (0.051) 
0.76 (0.006)* 
0.9 (0.283) 
0.68 (0.081) 
0 0.5 1 1.5 2
HR 
Legend
Hazard Ratio
p-value < 0.05
Page 22 of 44
http://mc.manuscriptcentral.com/jdt
Journal of Dermatological Treatment  www.informaworld.com/jdt
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
22 
 
 
 
Page 23 of 44
http://mc.manuscriptcentral.com/jdt
Journal of Dermatological Treatment  www.informaworld.com/jdt
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
1 
 
Long-term drug survival and predictor analysis of the whole psoriatic patient population on 
biological therapy in Hungary 
 
Lilla Pogácsás1,2, András Borsi3, Péter Takács4, Éva Remenyik2, Lajos Kemény5, Sarolta 
Kárpáti6, Péter Holló6, Norbert Wikonkál6, Rolland Gyulai7, Zsuzsanna Károlyi8, Pál Rakonczai9,  
Tamás Balázs9, Andrea Szegedi1,2 
 
1Division of Dermatological Allergology, 2Department of Dermatology, Faculty of Medicine, 
University of Debrecen, Debrecen, Hungary  
3Department of Health Economics, Market Access and Reimbursement, Janssen-Cilag Hungary 
Ltd., Budapest, Hungary 
4Real World Evidence Centre of Excellence, Janssen-Cilag Hungary Ltd., Budapest, Hungary 
5Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary 
6Department of Dermatovenerology and Dermatooncology, Semmelweis University, Budapest, 
Hungary 
7Department of Dermatology, Venereology and Oncodermatology, University of Pécs, Pécs, 
Hungary 
8Department of Dermatology, Semmelweis Hospital, Miskolc, Hungary 
9 Department of Research and Analysis Healthware Consulting Ltd., Budapest, Hungary 
 
Correspondence: 
Andrea Szegedi 
Division of Dermatological Allergology, Department of Dermatology, Faculty of Medicine, 
University of Debrecen, Hungary, 4032 Nagyerdei krt. 98., Debrecen, Hungary, 
aszegedi@med.unideb.hu, telephone and fax number: +36 52 255204, +36 52 255736 
Key words: biological therapy, comparison, hazard ratios, persistence, predictors, psoriasis 
 
 
 
Page 24 of 44
http://mc.manuscriptcentral.com/jdt
Journal of Dermatological Treatment  www.informaworld.com/jdt
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
2 
 
Long-term drug survival and predictor analysis of the whole psoriatic patient population on 
biological therapy in Hungary 
 
 
Abstract  
 
Persistence is an important component of therapeutic success, which depends on a variety of 
factors. Persistence measured under optimal conditions during clinical trials does not necessarily 
coincide with persistence observed in the real-world settings.   
The aim of the present study was to compare persistence rate of TNF-alpha inhibitors and 
interleukin 12/23 inhibitor in all psoriasis patients in Hungary, as well as to analyze the predictors 
of persistence. Data collected from 1263 patients over a period of 46 months were subjected to a 
retrospective analysis. Drug survival rate has been calculated according to Kaplan-Meier analysis 
and Cox regression was used to study the predictors.  
The overall persistence rate for the 4 biologicals exceeded 60% after 3 years. The persistence rate 
of ustekinumab at 3 years was 67.83%, which was superior compared to that of the TNF-alpha 
inhibitors, where the mean persistence rate was shown to be 50.76% (p<0.05). Male patients 
showed significantly higher persistence than females (HR = 0.76, p<0.05 CI: 0.63, 0.92). Age, 
therapy naïve status and use of concomitant MTX did not have significant effect on drug 
survival. Persistence rate of ustekinumab was significantly higher than that of TNF-alpha 
inhibitors, and among predictors, only male gender influenced persistence significantly. 
 
Key words: biological therapy, comparison, hazard ratios, persistence, predictors, psoriasis 
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Introduction  
 
Psoriasis is a common, chronic, immune-mediated skin disease. The disease and the 
comorbidities that frequently develop during its course not only impact the quality of life 
negatively, but also worsen life expectancy [1,2]. Epidemiological studies have shown that 
psoriasis patients have shorter life expectancy, particularly those who develop cardiovascular 
comorbidities [1]. Even though the disease is currently not curable, there are a number of 
therapeutic options which ensure a symptom-free status, although requires a long-term, often life-
long treatment [3,4]. Optimal drug survival is fundamental in the management of psoriasis and 
comorbidities [5]. 
Drug survival, i.e. persistence, is a comprehensive measure of therapeutic success, which depends 
on a variety of factors, including efficacy, safety, tolerability and patient satisfaction [5].   
Suboptimal persistence is a common and complex problem among patients with chronic diseases, 
including psoriasis [6, 7, 8]. Frequent switches between therapies and clinical research aiming to 
develop new therapeutic options to address persistence issues both confirm this [6]. An important 
breakthrough was the development of biological therapies, which became available for the 
treatment of moderate to severe psoriasis.  Biological therapies that are now widely available for 
psoriasis patients and include the TNF-α inhibitor adalimumab, infliximab, etanercept, the IL-
12/23 inhibitor ustekinumab, as well as the IL-17 inhibitor secukinumab and ixekizumab.   
 
Drug survival rate of biologicals seems to be better compared to local and conventional systemic 
therapies [9]. Persistence measured under optimal (standardized) conditions in prescreened, 
highly motivated patient populations, using tight protocols and independent investigators during 
clinical trials does not necessarily coincide with the drug survival of therapies prescribed in the 
real-world settings [10,11]. There are studies on the short-term persistence of biological therapies 
used in psoriasis, however, very limited comparative evidence is available on the long-term 
persistence of biological therapies used in the real-world settings [12]. The objectives of this 
study were to analyze the characteristics of all psoriasis patients treated with any of the biological 
therapies currently marketed in Hungary (adalimumab, etanercept, infliximab, ustekinumab), to 
compare long-term drug survival of such therapies in the real-world settings, and also to assess 
the impact of additional factors, like patient age, gender, biological therapy naïve status or the use 
of methotrexate (MTX) on drug survival.   
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Methods  
 
Patient enrollment  
The data source for this retrospective analysis was the database of the Hungarian National Health 
Insurance Fund (NHIF), which ensured the comparative analysis of all relevant data collected in 
the real-world settings. NHIF’s database covers healthcare data of the entire Hungarian 
population (nearly 10 million people) and allows identifying all patients in Hungary with a record 
of any reimbursed drug prescription and provides non-identified patient data on healthcare 
services and medical outcomes. Based on the available data provided by NHIF, it was possible to 
analyze patients’ age and gend r, onset of disease, the collected data of in- and outpatient care 
and previous therapies. As the NHIF database includes PASI and DLQI scores of psoriasis 
patients only since February 2012, PASI and DLQI scores were obtained from the registries of 
participating university centers instead of the NHIF database.  In Hungary patients suffering from 
psoriasis are eligible for biologic treatment in case of severe disease (PASI ≥ 15 or BSA ≥ 10 or 
DLQI ≥ 10) and documented intolerance or contraindication of standard systemic treatments. 
Hungarian Guideline on Psoriasis Therapies is based on and synchronized with the European S3 
Psoriasis Guideline in accordance with the financing protocol of the NHIF [13].  
All psoriasis patients, who started at least one biological therapy in Hungary, within the 46-
months study period from 1 June, 2010 to 1 April, 2014, were enrolled in this study.  Data of 
1574 treatment episodes of 1263 patients were analyzed (since some patients received more than 
one biological therapy over the study period, the number of treatment episodes exceeded the 
number of patients).  
Treatment discontinuation was defined by the occurrence of any of the following events: 
termination (no more prescription) or reinduction of the biological therapy (at least 180 days 
pause of biological therapy until the next prescription1), or switching to a different biological 
                                   
1
 Sensitivity analysis was carried out in order to identify the most appropriate gap length for treatment 
discontinuation. After a 180 day gap in the biological treatment there were only very limited number of patients 
who continued on the same treatment with no other biological treatment in between. These cases were 
considered as reinduction of biological therapy. 
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therapy. There were several reasons of treatment discontinuation however this kind of data were 
not captured in the NHIF registry. Since the authors have used the database of the NHIF no 
information was available on the reason of therapy discontinuation. Data were censored for 
patients where death of any cause occurred over the study period.  
 
 
Statistical methods applied  
 
Kaplan-Meier survival curve was used for the comparative analysis of drug survival. Cox 
proportional hazard model was applied to analyze the impact of patient age, gender, biological 
therapy naïve status and additional MTX therapy on drug survival. In order to compare patients’ 
baseline characteristics, conservative WALD test was used. ANOVA test, i.e. two-factor variance 
analysis was used to compare PASI and DLQI scores of treated patients as these are continuous 
variables. Mean PASI and DLQI scores were calculated using data collected from 641 patients 
treated by the 4 university centers.  
 
 
 
Results  
 
Patients’ baseline characteristics 
 
Data collected from a total number of 1263 patients were analyzed. Demographic data of patients 
are shown in Table 1.  
Although the vast majority of the enrolled patients, (n=972, 76.96%) received only one biological 
therapy over the study period, 18.69% (n=236) and 4.35% (n=55) of the patients were 
administered 2 and 3 or more biological therapies, respectively.  Since certain patients could have 
received several biological therapies due to the therapeutic switches, the number of treatment 
episodes (1574) exceeded the total patient number. All further data will refer to treatment 
episodes. 
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Patients’ characteristics were also analyzed and compared between subgroups receiving different 
biological therapies (Table 2).  The most frequently administered therapies were adalimumab and 
ustekinumab (n=491 and n=487, respectively), followed by etanercept (n=330), and infliximab 
(n=266) The analysis of each therapeutic groups showed that the distribution by gender, age and 
additional MTX usage was comparable among the different therapeutic groups, however, the 
ratio of biological therapy naïve patients was significantly different between the infliximab and 
adalimumab groups as well as between the ustekinumab and TNF-alpha inhibitors groups 
(p<0.05). Table 2 shows side-by-side comparison of data of various treatment groups comparing 
patient age, gender, additional MTX therapy, and biological therapy naïve status. Possible 
inhomogeneities in different treatment groups were handled by using all of these 4 grouping 
variables as covariates in the fitted Cox models, hence the findings on drug survival analysis 
were not impacted by them. The comparison of PASI (p=0.18) and DLQI (p=0.50) scores 
showed no significant differences among the 4 subgroups using different biological therapies.  
 
 
 
 
Drug survival of biological therapies  
 
 
The persistence was calculated by using the Kaplan-Meier method, and illustrated as a survival 
curve (Figure 1). The results of the database analysis showed that the drug survival rate of 
biological therapies in psoriasis patients is high as a whole, since the overall survival rates are 
79.70%, 68.52%, and 60.75% in the first, second, and third year of therapy, respectively. 
The cumulative data of the 3 TNF-alpha inhibitors showed that drug survival probability was 
73.28% in the first year, which dropped to 60.22% in the second year to decrease as low as 
50.76% in the third year.  
Kaplan-Meier survival analysis of the individual TNF-alpha inhibitors showed that drug survival 
of etanercept was 71.96% in the first year, which dropped to 60.03% one year later to reach 
49.49% after the third year. Drug survival of adalimumab and infliximab was 68.98% and 
70.92% in the first year, which dropped to 58.13% and 49.79% one year later to reach 51.95% 
and 36.26% after the third year respectively. The comparison of the drug survival rates of the 3 
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TNF-alpha inhibitors showed that adalimumab had the highest probability of patients staying on 
the therapy for three consecutive years, although based on Cox model results no significant 
difference among the 3 therapies could be detected. 
Drug survival rate of ustekinumab was 86.50% in the first year, 74.17% in the second year, and 
67.83% after the third year. The comparison of drug survival rates of ustekinumab and TNF-
alpha inhibitors showed that the persistence of ustekinumab was significantly higher if 
persistence was compared head-to-head with the TNF-alpha inhibitors (p<0.05), and this 
difference also persisted if ustekinumab was compared to the cumulative data of the 3 TNF-alpha 
inhibitors (p<0.05).  
 
Predictors of biological survival  
 
 
The Cox regression analysis of the impact of predictors such as patient age, gender, biological 
therapy naïve status and additional MTX use on persistence is shown in Figure 2. The analysis of 
all biological therapies together revealed that the probability of staying on the therapy was 
significantly higher in male patients than in female patients (p < 0.05, CI: 0.63, 0.92). Therapy 
naïve status, older age and the use of MTX all decreased the risk of dropping out of therapy, 
although the impact was not significant (Figure 2).  
The analysis of the cumulative data of all TNF-alpha inhibitor therapies revealed that the impact 
of patient gender was significant on drug survival: the risk of discontinuing the therapy was 0.71 
times lower for male patients compared with female patients. (HR=0.71, p<0.05, CI: 0.58, 0.87).  
The analysis of the individual therapy groups revealed the following: male gender had a 
favorable impact on the persistence of adalimumab (HR=0.73, p<0.05 CI: 0.54, 0.99) and 
infliximab (HR=0.71, p<0.05, CI: 0.49, 1) but did not influence the persistence of etanercept. 
Patients over 40 years on etanercept showed a significantly better persistence on the drug than 
patients younger than 40 years of age (HR=0.57, p<0.05, CI: 0.4, 0.81). None of the investigated 
predictors had a significant impact on drug survival of ustekinumab.   
 
Discussion 
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Suboptimal persistence was identified as a significant drawback in the management of psoriatic 
patients, which considerably hinders successful therapy, and can result in therapy discontinuation 
and increased treatment costs [6,7]. No conclusive findings have been reached so far regarding 
the long-term drug survival rates of biological therapies in psoriasis and predictors of their 
persistence. This study is the first long-term study performed in Hungary on the whole psoriatic 
patient population treated with biologicals, to analyze the drug survival of all available biological 
therapies and to investigate predictors of persistence in the real-life settings.  A further advantage 
of this study is that this is the first comprehensive analysis on this topic in the literature using the 
database of the NHIF of a given country.  
The analysis of the present study population showed that adalimumab and ustekinumab were 
administered to almost equal numbers of patients, while infliximab and etanercept were also used 
in identical proportions, although less commonly than the first two agents. Since all four 
biological therapies can be used under the same circumstances in Hungary, the choice of drug 
depended mostly on dermatologists’ preferences. The comparison of the subgroups receiving 
different biological therapies revealed that although there were certain differences among the 4 
therapy groups in terms of patients’ biological therapy naïve status, ultimately this factor didn’t 
prove to have statistically meaningful effect on drug persistence rate or on predictor analysis, 
since the statistical methods have addressed this issue. At the same time, no significant 
differences were found in terms of PASI and DLQI scores across the subgroups of patients on 
different biologicals. 
The available literature has already shown, that biological therapies used in psoriasis have 
superior drug survival rates compared to the rates seen with conventional systemic therapies [9].  
Nevertheless, until recently there was only a lack of data obtained on large patient population 
treated for long time with TNF-alpha inhibitors and IL-12/23 inhibitor in the real-life settings [11, 
14]. Table 3 summarizes all the studies published so far, where data were collected from large 
patient population of 2 or more centers, the follow-up period was at least one year, and the 
authors compared at least 3 or more biological therapies. The list includes 5 prospective registry-
based studies and 3 retrospective studies [5,11,15,16,17,18,19]. Table 3 shows, that those studies 
which included ustekinumab have found drug survival of ustekinumab superior to the drug 
survival of TNF-alpha inhibitors.  The largest study was published by Menter et al. analyzing 
data of 4000 patients taken from the PSOLAR registry, and their results indicated that drug 
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survival of ustekinumab was better than that of TNF-inhibitors for both biological-naïve and 
biological-experienced patients with psoriasis [19].  This concurs with the results from the British 
register (BADBIR) of 3523 bionaïve patients, where the drug survival rate of ustekinumab has 
been found nearly 80% at 3 years, which is significantly higher than that seen with TNF-
inhibitors [16]. Gniadecki et al. has also performed an updated study involving 1277 psoriasis 
patients treated with biological therapy and found that ustekinumab had the highest survival rate 
(81.9%) at 4 years, followed by adalimumab and infliximab. Between the TNF-inhibitors no 
significant differences were detected [11]. Our results are comparable to the above investigations, 
and showed that drug survival rates of biologic therapies were excellent compared to other 
therapies, even if they diminished over time: 79.70% after the first year, 68.52% after the second 
year and 60% after the third year. At 3 years, drug survival rates were 67.83% of ustekinumab, 
51.95% of adalimumab, 49.49% of etanercept, and 36.26% of infliximab. Our findings also 
showed that drug survival of ustekinumab was superior to TNF-alpha inhibitors, and the 
significant difference persisted over the 3-year study period. Adalimumab was shown to have the 
highest drug survival rate of all TNF- inhibitors studied, however, no significant difference was 
found among these drugs over the 46 months of the study period.  
In addition to the analysis of persistence rates, it is also very important to explore predictors of 
drug survival. No conclusive evidence has yet been provided on the predictors of biological drug 
survival in psoriasis. Studies done so far discussed the role of several factors such as PASI, 
DLQI, comorbidities, age, gender, weight, disease onset,  duration of psoriasis, presence of 
psoriatic arthritis, concomitant MTX or biological therapy naïve status and smoking. In Table 4 
we summarized results of long-term survival analyses performed on large psoriasis patient 
populations, investigating predictors of biological therapies only [11,15,17,19,20]. Three studies 
have shown that female gender is a predictor of discontinuation of biological therapies, 
[11,17,19] however Menter’s data are not directly comparable with the aforementioned studies 
since these authors analyzed biological naïve and experienced patients’ predictors separately. On 
the other hand other predictors of discontinuation like previous treatment with biologics, smoking 
status, higher DLQI, strict adherence to approved dose, presence of comorbidities, were detected 
only in one of the aforementioned investigations [11,15,17,19,20].  
Page 32 of 44
http://mc.manuscriptcentral.com/jdt
Journal of Dermatological Treatment  www.informaworld.com/jdt
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
10 
 
In the present study factors which could be extracted from the database of the NFIH were 
investigated. In accordance with the aforementioned authors, we could demonstrate the positive 
impact of male gender on the persistence of infliximab and adalimumab, while it had no effect on 
the persistence of ustekinumab and etanercept. It is not yet clear how gender impacts the 
persistence of biological therapy in psoriasis, but remarkably, female rheumatoid arthritis patients 
are also more likely to discontinue therapy than males [21]. Possible hypothetical explanations 
could be that female patients may develop anti-drug antibodies more frequently resulting in 
decreased therapeutic efficacy, or alternatively, psychological factors, such as dissatisfaction with 
treatment, may play more important role in females, but until now comparative studies were not 
performed.  
In our study in the etanercept group, patients over 40 years were more likely to stay on the 
therapy than their younger peers. To our knowledge, no other previous investigations showed 
similar effect of age on the persistence of biological therapies.  
In our study biological naive status and the use of MTX all decreased the risk of dropping out of 
therapy, although the impact was not significant. Biological therapy naïve status was shown to be 
a positive predictor for persistence in psoriasis by Gniadecki et al., and, similarly, Lopez-Ferrer 
could also demonstrate reduction of adalimumab drug survival in patients with prior exposure to 
another TNF-alpha inhibitor. On the other hand, there are studies which, similar to the current 
study did not find previous biological therapy usage as a negative predictor of persistence 
[11,15,19,20,23]. Although concomitant MTX usage has been shown to be associated with a 
better persistence of biologicals in rheumatological settings, there is no conclusive evidence in 
psoriasis about additional MTX as a positive predictor [24,25]. In a systematic review Bezooijen 
et al. selected eight studies, which generally showed that combination therapy of biologicals and 
MTX had higher efficacy than biological monotherapy, which could also indicate a positive 
effect of MTX on the drug survival, however, persistence was not investigated in this study [26]. 
On the other hand, Menter and colleagues unexpectedly reported that patients receiving MTX 
were significantly more likely to discontinue biological treatment compared with those without 
concomitant MTX in bionaïve  group, but not in biologic experienced patients [19]. Our present 
study did not show any significant impact of the addition of MTX to the biological therapy on 
drug survival rates of any of the biological drugs studied.  
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Based on the findings of this study drug survival rates of biologic therapies can be 
regarded as excellent as the vast majority of the patients (nearly 80%) received only one 
biological over the 3 years’ study period, and the mean survival rate did not diminish below 60% 
even after 3 years.  The IL-12/23 inhibitor ustekinumab was shown to have significantly better 
drug survival rate than the TNF-alpha inhibitors, and when analyzing consolidated data of all 
assessed biologic therapies, male patients had better persistence than female patients.  One of the 
advantages of the present study is that it is based on real-life data from the NHIF database, which 
allowed to analyze the whole psoriatic patient population treated with biological therapy in 
Hungary over a long period of time. 
 
 
Limitations of the study 
 
This is a retrospective analysis. Since the authors have used the database of the NHIF no 
information is available on the reason of therapy discontinuation. It is also worthwhile 
mentioning that while there is a patient support program for ustekinumab with potential impact 
on drug survival rates, there is no information available as to the existence of similar programs 
for the TNF-inhibitors.   An additional limitation of the study is that the NHIF database did not 
include the PASI and DLQI scores of patients on biological therapies, and, therefore, such data 
were taken from the databases of the participant university centers, and, as such, the data do not 
cover the full patient population.   
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       Table 1 Characteristics of the study population 
 
Number of patients 1263 
Mean age in years (SD) 49.3 (14.3) 
Male / female (%) 61.3 / 38.7 
Patients under 40 years / 40 years or above 
(%) 
29.3 / 70.7 
Biological therapy naïve / previously treated 
(%) 
81.3 / 18.7 
Number of patients receiving MTX in addition 
to the biological therapy  
97  
Mean PASI (SD) 20.5  (6.4) 
Mean DLQI (SD) 20.0  (5.8) 
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Table 2 Baseline characteristics of patients receiving different biological therapies and 
pairwise comparison of the 4 groups regarding gender, age, ratio of biological naïve patients 
and MTX usage 
 
 Therapy Adalimumab Etanercept Infliximab Ustekinumab 
Treatment episodes (1574) 491 (31.2%) 330 (21.0%) 266 (16.8%) 487 (31.0%) 
Mean age (SD) 47.24  (13.77) 47.55  (15.39) 49.92  (13.63) 47.71  (13.31) 
Male / Female % 59.1% / 40.9 56.4% / 43.6  64.3% / 35.7 61.4% / 38.6 
Patients under 40 years / 40 
years or above (%) 
33.0 / 67.0  31.5 / 68.5 22.9 / 77.1 31.2 / 68.8 
Biological therapy naïve / 
previously treated (%) 
64.4 / 35.6 73.2 / 26.8 77.8 / 22.2 50.1 / 49.9 
Patients receiving methotrexate 
in addition to the biological 
therapy (treatment episode) 
40 16 26 32 
 values of the conservative Wald tests, adjusted  
for the pairwise comparison of the proportion of  
 
gender  
Adalimumab - 1 1 1 
Etanercept 1 - 0.972 1 
Infliximab 1 0.972 - 1 
Ustekinumab 1 1 1 - 
 
age groups 
Adalimumab - 1 0.192 1 
Etanercept 1 - 0.385 1 
Infliximab 0.192 0.385 - 0.385 
Ustekinumab 1 1 0.385 - 
biological naïve patients  
Adalimumab - 0.106 0.012* 0.004* 
Etanercept 0.106 - 0.356 <0.001* 
Infliximab 0.012* 0.356 - <0.001* 
Ustekinumab 0.004* <0.001* <0.001* - 
patients receiving MTX in addition to the biological therapy  
Adalimumab - 0.85 1 1 
Etanercept 0.85 - 0.6 1 
Infliximab 1 0.6 - 1 
Ustekinumab 1 1 1 - 
Data are reported for treatment episodes   
*significant differences 
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Table 3 Studies on long term drug survival of biological therapies in psoriasis  
 
Data of those studies are summarized, which investigated persistence of at least 3 biologicals 
and were collected on large psoriasis patient population of 2 or more centers and over long 
follow up period (least one year). IFN: infliximab, ADA: adalimumab, ETN: etanercept, UST: 
ustekinumab 
 
Study Biologics 
Patients/Treatme
nt periods 
Follow-up 
time 
(months) 
Best survival 
Source/ 
regimen 
R. Gniadecki et 
al. (2011) 
ADA, ETN, 
INF 
 
747 patients/882 
treatment episodes 
 
48 INF (70%) 
DERMBIO; Danish 
prospective registry 
M. Esposito et 
al. (2013) 
ADA, ETN, 
INF 
650 patients 28.9 ± 15.4 ETN (72.6%)  
Retrospective analysis 
from three Italian 
referral centers 
van der Reek et 
al. (2014) 
ADA, ETN, 
UST 
249 treatment 
episodes 
12 UST (85%) 
Bio-CAPTURE Dutch   
prospective registry  
R.B. Warren et 
al. (2015) 
ADA, ETN,  
INF, UST 
3523 patients 36 UST 
BADBIR registry; 
Prospective British 
cohort study 
R. Gniadecki et 
al. (2015) 
ADA, ETN, 
INF, UST 
1277 patients/1867 
treatment episodes 
followed for 
up to 10 
years 
UST (81.9% 
after 5 years) 
DERMBIO Danish 
prospective registry 
E. Vilarrasa et 
al. (2016) 
ADA, ETN, 
INF, UST 
427 patients/703 
treatment episodes 
48  UST  
retrospective study, 
from 2 Spanish center 
A. Menter et al 
(2016) 
ADA, ETN, 
INF, UST 
4000 patients 74  UST 
PSOLAR; prospective 
registry from USA and 
European countries 
L. Pogácsás et 
al. (2016) 
ADA, ETN, 
INF, UST 
1263 patients/1574 
treatment episodes 
46 UST 67.83% 
retrospective study, 
database of NHIF, 
Hungary 
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Table 4 Studies on the predictors of biological therapies in psoriasis 
 
 
Study Biologics 
Examined 
predictors/covariates 
Significant covariates 
R. Gniadecki et al. (2015) 
INF, ADA, ETN, UST 
1277 patients/1867 treatment 
episodes 
age, sex, previous biologic 
treatment, weight, duration 
of psoriasis, presence of 
PsA, baseline PASI and 
DLQI, concomitant MTX, 
number of co-morbidities 
predictors of 
discontinuation: female 
gender; previous biologic 
treatment  
R.B. Warren et al. (2015) 
INF, ADA,  ETN, UST 
3523 patients 
age, sex, BMI, smoking 
status, presence of PsA, 
number of co-morbidities, 
disease duration, disease 
onset, PASI, DLQI, 
unstable psoriasis, 
concomitant MTX, 
concomitant cyclosporine 
predictors of 
discontinuation: female 
gender, being current 
smoker, higher DLQI 
predictors of drug 
survival: presence of PsA 
A. Menter et al. (2016) 
INF, ADA, ETN, UST 
4000 patients 
age, gender, ethnicity, 
BMI, familial psoriasis 
history, smoking status, 
alcohol use status, duration 
of psoriasis, age at the 
diagnosis of psoriasis, 
presence of PsA, study 
site/geographic region, 
history of 
immunmodulator use, 
types of insurance, 
previous biologic 
treatment, reasons for 
discontinuation of prior 
biologics, PSA, 
concomitant MTX use 
predictors of 
discontinuation: in bio 
naïve patients: 
concomitant MTX, female 
gender and geographic 
region (North America vs. 
Latin America) 
E. Vilarrasa et al. (2016) 
INF, ADA,  ETN, UST 
427 patients 
sex, presence of PsA, 
biologic naïve status, use 
of combination treatment, 
weight, strict adherence to 
approved doses, PASI75 
and PASI 90 response 
predictors of 
discontinuation obesity,  
strict adherence to 
approved doses;  
predictors of drug 
survival: PASI75 and 
PASI90 response at week 
16  
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A. Jacobi et al. (2016) 
INF, ADA, ETN, UST, 
Efalizumab 
125 treatment episodes 
biologic naïve status, 
presence of PsA, and 
comorbidity with the 
presence of metabolic 
syndrome 
 
predictors of 
discontinuation: 
comorbidities  
 
predictors of drug 
survival: presence of PsA 
L. Pogácsás et al. (2016) 
INF, ADA, ETN, UST 
1263 patients/1574 treatment 
episodes 
gender, age, additional 
MTX therapy, biologic 
naïve status 
predictors of 
discontinuation: female 
gender 
Data of those studies are summarized, which investigated predictors of at least 3 biologicals 
and were collected on large psoriasis patient population and over long follow up period (least 
one year).  
IFN: infliximab, ADA: adalimumab, ETN: etanercept, UST: ustekinumab MTX: methotrexate 
PASI: psoriasis area severity index, DLQI: Dermatology Life Quality Index 
PSA: Physician’s Global Assessment  
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Fig. 1. Kaplan-Meier survival curve of the 4 biologicals individually and in summary (all biological therapies). 
Data include 1574 treatment episodes. 491 adalimumab treatment series, 330 etanercept series, 266 
infliximab series, and 487 ustekinumab series.  
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Fig. 2. Multivariate analysis of predictors on biological therapies’ persistence rate (Cox proportional hazard 
and regression model). The figure shows the risk of drop out of therapy by predictors such as patient age, 
gender, biological therapy naïve status and additional MTX usage.  
1Reference category: Age<=40  
2Reference category: female gender  
3Reference category: biological-experienced patients  
4Reference category: patients who do not receive MTX  
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